The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy

Clinical Transplantation

Volumn 28, Issue 6, 2014, Pages 635-648

  Klintmalm, Goran B ^a   Saab, Sammy ^b   Hong, Johnny C ^c   Nashan, Björn ^d  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cyclosporine; Everolimus; Malignancy; Mammalian target of rapamycin; Sirolimus; Tacrolimus; Transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RIDAFOROLIMUS; STEROID; TACROLIMUS; TEMSIROLIMUS; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CANCER CONTROL; CANCER PREVENTION; CANCER REGRESSION; CANCER RISK; DRUG INDUCED CANCER; DRUG SAFETY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; NONHUMAN; ONCOLOGY; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; POSTTRANSPLANT MALIGNANCY; PRIORITY JOURNAL; REVIEW; SKIN CANCER; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR;

ANTINEOPLASTIC AGENTS; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84901929399     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12357     Document Type: Review

References (100)

1. Organ Procurement and Transplantation Network (OPTN). Transplants in the US by State, January 1, 1988 to August 31, 2013. Available at: http://optn.transplant.hrsa.gov/latestdata/rptdata.asp. Accessed November 2013.
2. Domhan S, Zeier M, Abdollahi A. Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant 2009: 24: 1097.
3. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 2007: 22(Suppl. 1): i4.
4. Kim PT, Onaca N, Chinnakotla S et al. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation. Clin Transplant 2013: 27: 311.
5. Goldstein RM, Stone M, Tillery GW et al. Is liver transplantation indicated for cholangiocarcinoma? Am J Surg 1993: 166: 768.
6. Hong JC, Jones CM, Duffy JP et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 2011: 146: 683.
7. Singh MK, Brewer JD. Current approaches to skin cancer management in organ transplant recipients. Semin Cutan Med Surg 2011: 30: 35.
8. Apel H, Walschburger-Zorn K, Häberle L, Wach S, Engehausen DG, Wullich B. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr. Clin Transplant 2013: 27: E30.
9. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004: 4: 905.
10. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999: 40(2 Pt 1): 177.
11. Na R, Grulich AE, Meagher NS, McCaughan GW, Keogh AM, Vajdic CM. De novo cancer-related death in Australian liver and cardiothoracic transplant recipients. Am J Transplant 2013: 13: 1296.
12. Roayaie S, Schwartz JD, Sung MW et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004: 10: 534.
13. Zendejas-Ruiz I, Hemming AW, Chen C, Schwartz JJ, Sorensen JB, Kim RD. Recurrent hepatocellular carcinoma in liver transplant recipients with hepatitis C. J Gastrointest Cancer 2012: 43: 229.
14. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975: 28: 721.
15. Sehgal SN, Baker H, Vézina C. Rapamycin (AY-22, 989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975: 28: 727.
16. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977: 55: 48.
17. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981: 8: 63.
18. Houchens DP, Ovejera AA, Riblet SM, Slagel DE. Human brain tumor xenografts in nude mice as a chemotherapy model. Eur J Cancer Clin Oncol 1983: 19: 799.
19. Eng CP, Sehgal SN, Vézina C. Activity of rapamycin (AY-22, 989) against transplanted tumors. J Antibiot (Tokyo) 1984: 37: 1231.
20. Dancey JE. Therapeutic targets: mTOR and related pathways. Cancer Biol Ther 2006: 5: 1065.
21. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002: 8: 128.
22. Nichols LA, Adang LA, Kedes DH. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS One 2011: 6: e14535.
23. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005: 352: 1317.
24. Reardon DA, Quinn JA, Vredenburgh JJ et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 2006: 12: 860.
25. Rizell M, Andersson M, Cahlin C, Hafstrom L, Olausson M, Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 2008: 13: 66.
26. Desar IM, Timmer-Bonte JN, Burger DM, van der Graaf WT, van Herpen CM. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer. Br J Cancer 2010: 103: 1637.
27. Gangadhar TC, Cohen EE, Wu K et al. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res 2011: 17: 1956.
28. Jimeno A, Rudek MA, Kulesza P et al. Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 2008: 26: 4172.
29. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007: 356: 2271.
30. Kwitkowski VE, Prowell TM, Ibrahim A et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010: 15: 428.
31. Wyeth Pharmaceuticals, Inc. Torisel Kit (Temsirolimus) Injection [Prescribing Information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., 2012.
32. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009: 27: 3822.
33. Smith SM, van Besien K, Karrison T et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010: 28: 4740.
34. Oza AM, Elit L, Tsao MS et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011: 29: 3278.
35. Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005: 23: 5314.
36. Wolff AC, Lazar AA, Bondarenko I et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2013: 31: 195.
37. Novartis Pharmaceuticals Corporation. Afinitor (Everolimus) [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012.
38. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012: 366: 520.
39. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010: 116: 4256.
40. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011: 364: 514.
41. Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol 2012: 7: 1594.
42. Slomovitz BM, Lu KH, Johnston T et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010: 116: 5415.
43. Doi T, Muro K, Boku N et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010: 28: 1904.
44. Seront E, Rottey S, Sautois B et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol 2012: 23: 2663.
45. Renner C, Zinzani PL, Gressin R et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012: 97: 1085.
46. Johnston PB, Inwards DJ, Colgan JP et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010: 85: 320.
47. Ghobrial IM, Gertz M, Laplant B et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010: 28: 1408.
48. Ewald F, Grabinski N, Grottke A et al. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. Int J Cancer 2013: 133: 2065.
49. Grabinski N, Ewald F, Hofmann BT et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012: 11: 85.
50. Villanueva A, Chiang DY, Newell P et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008: 135: 1972.
51. Zhu AX, Abrams TA, Miksad R et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011: 117: 5094.
52. Chawla SP, Staddon AP, Baker LH et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012: 30: 78.
53. Chawla SP, Blay J, Ray-Coquard IL et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 2011: 29(15 Suppl.): Abstract 10005.
54. Colombo N, McMeekin DS, Schwartz PE et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 2013: 108: 1021.
55. Schuurman HJ, Cottens S, Fuchs S et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997: 64: 32.
56. Schuler W, Sedrani R, Cottens S et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997: 64: 36.
57. Wyeth Pharmaceuticals, Inc. Rapamune (Sirolimus) Oral Solution and Tablets [Prescribing Information]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., 2011.
58. Novartis Pharmaceuticals Corporation. Zortress (Everolimus) Tablets for Oral Use [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012.
59. Ciancio G, Burke GW, Gaynor JJ et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006: 81: 845.
60. Russ GR, Campbell S, Chadban S et al. Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. Transplant Proc 2003: 35: 115S.
61. MacDonald AS, The RAPAMUNE Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001: 71: 271.
62. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000: 356: 194.
63. Campsen J, Zimmerman MA, Mandell S, Kaplan M, Kam I. A decade of experience using mTOR inhibitors in liver transplantation. J Transplant 2011: 2011: 913094.
64. Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl 2012: 18: 1029.
65. Cibrik D, Silva HT Jr, Vathsala A et al. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplantation 2013: 95: 933.
66. Langer RM, Hené R, Vitko S et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int 2012: 25: 592.
67. Fischer L, Klempnauer J, Beckebaum S et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation - PROTECT. Am J Transplant 2012: 12: 1855.
68. De Simone P, Nevens F, De Carlis L et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012: 12: 3008.
69. Saliba F, De Simone P, Nevens F et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013: 13: 1734.
70. Suthanthiran M, Hojo M, Maluccio M, Boffa DJ, Luan FL. Post-transplantation malignancy: a cell autonomous mechanism with implications for therapy. Trans Am Clin Climatol Assoc 2009: 120: 369.
71. Walsh SB, Xu J, Xu H et al. Cyclosporine a mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial-mesenchymal transition: role of TGFbeta signaling pathway. Mol Carcinog 2011: 50: 516.
72. Tjon AS, Sint Nicolaas J, Kwekkeboom J et al. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl 2010: 16: 837.
73. Rodríguez-Perálvarez M, Germani G, Papastergiou V et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. J Hepatol 2013: 58: 262.
74. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998: 351: 623.
75. Vivarelli M, Cucchetti A, La Barba G et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008: 248: 857.
76. Vivarelli M, Cucchetti A, Piscaglia F et al. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005: 11: 497.
77. Hong JC, Kahan BD. Use of anti-CD25 monoclonal antibody in combination with rapamycin to eliminate cyclosporine treatment during the induction phase of immunosuppression. Transplantation 1999: 68: 701.
78. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004: 18: 446.
79. Schena FP, Pascoe MD, Alberu J et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009: 87: 233.
80. Guba M, Pratschke J, Hugo C et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36 months after transplantation. Transpl Int 2012: 25: 416.
81. Chiurchiu C, Carreño CA, Schiavelli R et al. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies. Transplant Proc 2010: 42: 277.
82. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005: 80: 883.
83. Hong JC, Petrowsky H, Kaldas FM et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma. J Am Coll Surg 2011: 212: 514.
84. Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl Int 2012: 25: 1158.
85. Liang W, Wang D, Ling X et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012: 18: 62.
86. Schnitzbauer AA, Zuelke C, Graeb C et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010: 10: 190.
87. UPDATE 1-Novartis drug shows no survival benefit in liver cancer. Available at: http://www.reuters.com/article/2013/08/07/novartis-afinitor-idUSL6N0G818R20130807. Accessed November 14, 2013.
88. Salgo R, Gossmann J, Schöfer H et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010: 10: 1385.
89. Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012: 367: 329.
90. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006: 17: 581.
91. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012: 12: 1146.
92. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013: 31: 1317.
93. Caroti L, Zanazzi M, Paudice N et al. Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin. Transplant Proc 2012: 44: 1926.
94. Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients-the impact of proliferation signal inhibitors. Nephrol Dial Transplant 2007: 22(Suppl. 1): i17.
95. Yaich S, Charfeddine K, Zaghdane S et al. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Transplant Proc 2012: 44: 2824.
96. Majewski M, Korecka M, Kossev P et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000: 97: 4285.
97. Cullis B, D'Souza R, McCullagh P et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006: 47: e67.
98. Pascual J. Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007: 22(Suppl. 1): i27.
99. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2011 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation. Available at: http://srtr.transplant.hrsa.gov/annual_reports/2011/pdf/2011_srtr_adr.pdf. Accessed January 22, 2014.
100. Engels EA, Pfeiffer RM, Fraumeni JF Jr et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011: 306: 1891.